Generali Investments Towarzystwo Funduszy Inwestycyjnych Intellia Therapeutics, Inc. Transaction History
Generali Investments Towarzystwo Funduszy Inwestycyjnych
- $189 Billion
- Q3 2025
A detailed history of Generali Investments Towarzystwo Funduszy Inwestycyjnych transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Generali Investments Towarzystwo Funduszy Inwestycyjnych holds 80,000 shares of NTLA stock, worth $696,000. This represents 0.73% of its overall portfolio holdings.
Number of Shares
80,000
Previous 100,000
20.0%
Holding current value
$696,000
Previous $938 Million
47.29%
% of portfolio
0.73%
Previous 0.49%
Shares
10 transactions
Others Institutions Holding NTLA
# of Institutions
344Shares Held
103MCall Options Held
3.16MPut Options Held
1.56M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$104 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$96.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$83.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.02MShares$52.4 Million0.01% of portfolio
-
Contrarius Group Holdings LTD Hamilton, D05.89MShares$51.2 Million4.6% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $661M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...